Medicine, Antibiotics Exports Gaining Share In US, Italian Markets: Govt Data According To The Commerce Ministry Data, India

New Delhi: With the Union government focusing on boosting domestic manufacturing of pharmaceutical products, India’s medicine and antibiotics exports have started gaining significant market share in the US.

According to the commerce ministry data, India is the third largest import source of ‘medicine put up for retail sale’ for the US. The top two are Ireland and Switzerland.

In 2023, the country exported these medicines worth $9 billion as against $7.33 billion in 2022.

With this increase in the shipments, India’s share went up to 13.1 percent in 2023 from 10.08 percent in 2022. Share of the top exporter Ireland fell to 13.85 percent in 2023 from 17.18 percent in 2022 because its sales in the US went down to $9.5 billion in 2023 from $12.5 billion in 2022.

The second biggest exporter Switzerland also saw its share decline to 13.7 percent last year from 17.4 percent in 2022.

Similarly, India has increased its share among exporters of antibiotics in the Italian market. It is ranked 10th in that market by increasing its share to 2.12 percent in 2023 from 0.96 percent in 2022.

In value terms, the country’s antibiotics exports to Italy stood at $23.34 million in 2023 as against $11.48 million in 2022.

Further, the data showed that India’s competitiveness is growing in the Magnetic Resonance Imaging (MRI) apparatus market of Germany.

In 2023, the country made a small gain by increasing its export share in Germany to 1.7 percent from 0.45 per cent in 2022.

In value terms, India exported these MRI machines worth $13.02 million last year as against $2.93 million in 2022.

India is the sixth largest exporter of MRI apparatus, whereas the UK is the leader with exports of $460 million.

“Penetrating the EU market is difficult and it is important that we have a base coming in. These reflect some efforts which are being put in terms of monitoring various markets and various commodities to see where growth can be pushed,” an official said.

Pharma and medical devices manufacturing is the priority area for the government and these two sectors were the first ones to get a Production Linked Incentive (PLI) scheme.

Related Posts

Senores Pharmaceuticals to Acquire Apnar Pharma at Enterprise Value of ₹91 Crore

Gujarat based Senores Pharmaceuticals Ltd on Monday, December 15, announced that it has entered into a share purchase agreement to acquire a 100% equity stake in Apnar Pharma Private Ltd.…

Aytu BioPharma launches depression drug EXXUA in U.S. market

DENVER-  Aytu BioPharma, Inc. (NASDAQ:AYTU) announced Monday the commercial availability of EXXUA in the United States for the treatment of major depressive disorder (MDD). The small-cap biotech, with a market…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Senores Pharmaceuticals to Acquire Apnar Pharma at Enterprise Value of ₹91 Crore

Senores Pharmaceuticals to Acquire Apnar Pharma at Enterprise Value of ₹91 Crore

Aytu BioPharma launches depression drug EXXUA in U.S. market

Aytu BioPharma launches depression drug EXXUA in U.S. market

Delhi govt carries out 27 raids against fake medicine

Delhi govt carries out 27 raids against fake medicine

Odisha Pharma Summit 2025 to Explore Opportunities in Pharmaceutical Sector on December 16

Odisha Pharma Summit 2025 to Explore Opportunities in Pharmaceutical Sector on December 16

ITS in AMTZ, 70 Countries participated for Future of Health Technology

ITS in AMTZ, 70 Countries participated for Future of Health Technology

Glenmark Pharmaceuticals Ltd soars 0.2%, gains for fifth straight session

Glenmark Pharmaceuticals Ltd soars 0.2%, gains for fifth straight session